Figure 5.
Figure 5. BMT with BM from diseased rats and specificity of protection. (A) DA rats were immunized with MOG 1-125 in CFA on day 0 and boosted with MOG 1-125 in incomplete Freund adjuvant (IFA) on day 18. Subsequently, they received a BM transplant on day 36 from DA rats with EAE (n = 9). Control rats received no BM transplant (n = 9). (B) A subgroup of rats after transplantation of BM from diseased rats (n = 4) and naive rats (naive BMT; n = 5) were immunized with MOG 1-125. Naive rats developed EAE while rats that had received BM from diseased rats did not relapse. (C) DA rats after BMT (DA BM from diseased rats; n = 4) and rats that were naive at the time of transplantation (naive BMT; n = 4) were immunized with MBP 63-88 on day 79. Both groups developed EAE after immunization with MBP 63-88, indicating specificity of BMT-induced tolerance.

BMT with BM from diseased rats and specificity of protection. (A) DA rats were immunized with MOG 1-125 in CFA on day 0 and boosted with MOG 1-125 in incomplete Freund adjuvant (IFA) on day 18. Subsequently, they received a BM transplant on day 36 from DA rats with EAE (n = 9). Control rats received no BM transplant (n = 9). (B) A subgroup of rats after transplantation of BM from diseased rats (n = 4) and naive rats (naive BMT; n = 5) were immunized with MOG 1-125. Naive rats developed EAE while rats that had received BM from diseased rats did not relapse. (C) DA rats after BMT (DA BM from diseased rats; n = 4) and rats that were naive at the time of transplantation (naive BMT; n = 4) were immunized with MBP 63-88 on day 79. Both groups developed EAE after immunization with MBP 63-88, indicating specificity of BMT-induced tolerance.

Close Modal

or Create an Account

Close Modal
Close Modal